Adjuvant and neoadjuvant therapy for breast cancer

Japanese Journal of Clinical Oncology
Tadahiko Shien, Hiroji Iwata

Abstract

Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target drugs and regimens are being developed based on the predicted sensitivity for specific breast cancer histological types. Systemic therapy is selected according to recurrence risk, with the treatment for low-risk patients being de-escalated, while high-risk patients receive aggressive systemic treatment with an adequate dose and duration. Neoadjuvant systemic therapy has a different aim. The efficacy of systemic therapies, based on the sensitivities to drugs, is supported by improvements in the rate of breast-conserving therapy. The response to neoadjuvant systemic therapy is the most important factor for predicting outcomes and selecting the optimal adjuvant therapy. Novel biological markers unique to individual patients allow appropriate targeted therapy, which can achieve optimal efficacy.

References

Dec 8, 2005·Journal of the National Cancer Institute·Marco VenturiniPaolo Bruzzi
Apr 20, 2007·The Cochrane Database of Systematic Reviews·J S D MieogC J H van de Velde
Jan 31, 2008·Journal of the National Cancer Institute·Giuseppe VialeUNKNOWN International Breast Cancer Study Group
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen JonesMichael A Savin
Oct 14, 2011·The New England Journal of Medicine·Dennis SlamonUNKNOWN Breast Cancer International Research Group
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Jul 3, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettJack Cuzick
Jun 3, 2014·The New England Journal of Medicine·Olivia PaganiUNKNOWN International Breast Cancer Study Group
Jan 8, 2015·The New England Journal of Medicine·Sara M TolaneyEric P Winer
Jun 5, 2015·Lancet·Michael GnantUNKNOWN Austrian Breast and Colorectal Cancer Study Group
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Jul 28, 2015·Lancet·UNKNOWN Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Sep 29, 2015·The New England Journal of Medicine·Joseph A SparanoGeorge W Sledge
Apr 6, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meredith M ReganRichard D Gelber
Jun 7, 2016·The New England Journal of Medicine·Paul E GossWendy R Parulekar
Apr 12, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joanne L BlumNorman Wolmark
Jun 1, 2017·The New England Journal of Medicine·Norikazu MasudaMasakazu Toi
Jun 28, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Poornima SahaUNKNOWN International Breast Cancer Study Group
Jul 13, 2017·The New England Journal of Medicine
Dec 6, 2018·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN KATHERINE Investigators

❮ Previous
Next ❯

Citations

Dec 29, 2020·Japanese Journal of Clinical Oncology·Hideo Kunitoh
Jan 1, 2021·Cancers·Miguel A OrtegaMiguel A Álvarez-Mon
Mar 5, 2021·Esophagus : Official Journal of the Japan Esophageal Society·Daisuke UjiieKoji Kono
Apr 17, 2021·Future Oncology·Sara SpinelliGiandomenico Roviello
Jun 18, 2021·Frontiers in Oncology·Carolina MathiasJaqueline Carvalho de Oliveira

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.